about
Chronic obstructive pulmonary diseaseLeupeptin inhibits ventilator-induced diaphragm dysfunction in ratsInspiratory muscle training protocol for patients with chronic obstructive pulmonary disease (IMTCO study): a multicentre randomised controlled trial.Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.Inhospital management of COPD exacerbations: a systematic review of the literature with regard to adherence to international guidelines.An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.Standardizing the analysis of physical activity in patients with COPD following a pulmonary rehabilitation programApocynin attenuates diaphragm oxidative stress and protease activation during prolonged mechanical ventilation.Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor.Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats.The impact of care pathways for exacerbation of Chronic Obstructive Pulmonary Disease: rationale and design of a cluster randomized controlled trial.Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortalityGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD.Cardiovascular safety of tiotropium in patients with COPD.Proprioceptive changes impair balance control in individuals with chronic obstructive pulmonary diseaseAnnual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPDA 4-year trial of tiotropium in chronic obstructive pulmonary disease.Moderate intense physical activity depends on selected Metabolic Equivalent of Task (MET) cut-off and type of data analysis.Impaired postural control reduces sit-to-stand-to-sit performance in individuals with chronic obstructive pulmonary disease.Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial.Acute lung allograft rejection: diagnostic role of probe-based confocal laser endomicroscopy of the respiratory tract.Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trialsTiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trialAdverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trialNoninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study.Exercise training during rehabilitation of patients with COPD: a current perspective.Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.Chronic obstructive pulmonary disease and chronic heart failure: two muscle diseases?Airways resistance and specific conductance for the diagnosis of obstructive airways diseases.Physical Activity Counselling during Pulmonary Rehabilitation in Patients with COPD: A Randomised Controlled Trial.Pulmonary rehabilitation in chronic obstructive pulmonary disease.Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease.Exacerbation frequency and course of COPD.Physical inactivity in patients with COPD, a controlled multi-center pilot-study.Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial.The role of bronchodilator treatment in the prevention of exacerbations of COPD.Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbationImpact of exacerbations of cystic fibrosis on muscle strength
P50
Q28259151-0E4F2B54-74A3-49B5-8CB2-08230522C8A5Q28575964-E6A3A424-7089-4B62-8153-B060F5FC0C95Q30450921-ED54769E-1C6A-49EB-8D90-8148BCEEF1C5Q30990525-0D8FCEE3-07BD-4232-ACFB-DC78FC8C213AQ33549542-3DA8CFB1-DBC2-48AB-A643-0BA575640ED2Q33901722-C5C7C998-B94E-40BE-95A2-AA8739B160C6Q34004353-958D03C4-0DEE-4706-B374-859C9CB6AA77Q34016668-7B9C5376-C7B4-4AAF-B102-CF8F54B7BB2EQ34250031-1CBB44CE-9876-4337-A1D8-F2D3DCE29932Q34394314-5D4D32FD-FEF3-4BC7-8CD6-DEA786D6C424Q34403397-C47A1DD0-1E6B-4C13-80C9-FAAC9F8719A4Q34510698-9326BADB-0FBF-4157-A975-E06724C08C5BQ34550471-40DF9617-C4FB-441E-9297-4A724F0D69CAQ34557270-3089E1C5-E8D3-4D36-BB5E-0F845FB46603Q34571675-68746A9F-6699-4A49-9AAD-BB7A2C794A02Q34609804-9A4299E1-EACB-4E10-86AC-5FB2E1F6EA34Q34613356-6031FE54-5B7A-40F9-AEDC-FBBCC4837945Q34823949-B6907E48-38DC-4CB5-B684-D61EFEFB55D2Q34845834-DC7B8017-7A14-4BD5-9D5E-2957C62B787BQ35078375-3899DA8E-685F-4A74-AF80-30112223EE85Q35095300-68740BFB-A893-4E9A-A1DE-0D89D62D69F7Q35120004-3ABF8E7F-0A7C-46B2-AB94-30053E5EAAE7Q35127603-9FA262F9-F643-48A0-83B7-02DFC948B11FQ35153689-1880BA50-E232-481C-A5AE-89A8F7729952Q35215919-4741A592-D00E-4B51-B223-840AB52C2C1DQ35305509-A1DA5515-1608-4945-B3EC-D52195C5704CQ35542051-EE0D21A6-3A69-4B0F-9751-C8AADB6706E4Q35681418-F9A14103-0841-4184-892E-B99E6FB695F9Q35762406-C19226FF-306B-4C92-94DD-F04EED6FF0B1Q35827210-E751F36B-B63E-4C36-9078-CCF68C647A81Q35875246-B121BD5E-BBA5-4DE6-882F-3280CBFFF5C8Q35876427-7AC5ECD1-9466-4B1D-A833-FA01E939D0AAQ36075213-658476FA-90F2-4D83-8B42-D0BA6C7F2167Q36235837-55E3AE82-C2BD-4C4D-8278-9207820134B2Q36283928-EF70874B-723E-49E0-A820-FC94C9EA8DB3Q36318987-62DA4F1C-0316-422E-8117-5BFFD878209EQ36384145-E47701FE-5CFC-4C53-ACE8-995A9105FD83Q36438669-335C114B-AEAD-4A74-B631-576360191EAEQ36526988-5EE4F565-147B-4E6A-9B5B-7CFE74CB2B46Q36798427-03F986CA-22DF-42CF-B5CA-4BEC113CE7E9
P50
name
Marc Decramer
@ast
Marc Decramer
@en
Marc Decramer
@es
Marc Decramer
@nl
type
label
Marc Decramer
@ast
Marc Decramer
@en
Marc Decramer
@es
Marc Decramer
@nl
prefLabel
Marc Decramer
@ast
Marc Decramer
@en
Marc Decramer
@es
Marc Decramer
@nl
P214
P21
P214
P31
P735
P7859
lccn-n00138599